Fiserv, Inc. (NASDAQ:FISV) and Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) are both Services companies that recently hit new highs. This price action has ruffled more than a few feathers in the investment community, but is one a better investment than the other? To answer this, we will compare the two companies across growth, profitability, risk, return, dividends, and valuation measures.Fiserv, Inc. (NASDAQ:FISV) operates in the Business Services segment of the Services sector. The company has grown sales at a 5.10% annual rate over the past five years, putting it in the medium growth category. FISV has a net profit margin of 16.30% and is more profitable than the average company in the Business Services industry. In terms of efficiency, FISV has an asset turnover ratio of 0.57. This figure represents the amount of revenue a company generates per dollar of assets. FISV’s financial leverage ratio is 3.34, which indicates that the company’s asset base is primarily funded by debt. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 37.70%, which is better than the Business Services industry average ROE.Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is 0.91. Company trades at a P/E ratio of 30.50, and is more expensive than the average stock in the Business Services industry. The average investment recommendation for FISV, taken from a group of Wall Street Analysts, is 2.40, or a buy.Over the past three months, Fiserv, Inc. insiders have been net buyers, dumping a net of -159,949 shares. This implies that insiders have been feeling relatively bearish about the outlook for FISV. Insider activity and sentiment signals are important to monitor because they can shed light on how “risky” a stock is perceived to be at it’s current valuation. Knowing this, it makes sense to look at beta, a measure of market risk. FISV has a beta of 0.83 and therefore an below average level of market volatility.
     (adsbygoogle = window.adsbygoogle || []).push({});
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) operates in the Business Services segment of the Services sector. IDXG has increased sales at a -39.20% CAGR over the past five years, and is considered a low growth stock. The company has a net profit margin of -7.70% and is less profitable than the average Business Services player. IDXG’s asset turnover ratio is 0.3 and the company has financial leverage of 0.39. IDXG’s return on equity of -6.90% is worse than the Business Services industry average.The company trades at a free cash flow yield of -39.5 and has a P/E of 0.39. Compared to the average company in the 27.19 space, IDXG is relatively cheap. The average analyst recommendation for IDXG is 2.00, or a buy.Interpace Diagnostics Group, Inc. insiders have sold a net of 0 shares during the past three months, which implies that the company’s top executives have been feeling bearish about the stock’s outlook. Finally, IDXG’s beta of 1.63 indicates that the stock has an below average level of market risk.Fiserv, Inc. (NASDAQ:FISV) scores higher than Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) on 6 of the 13 measures compared between the two companies. FISV has the better fundamentals, scoring higher on growth, profitability, efficiency and return metrics.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.